MX2009006410A - Conjugados de polimero-oligonucleotido, proteina y/o peptido. - Google Patents
Conjugados de polimero-oligonucleotido, proteina y/o peptido.Info
- Publication number
- MX2009006410A MX2009006410A MX2009006410A MX2009006410A MX2009006410A MX 2009006410 A MX2009006410 A MX 2009006410A MX 2009006410 A MX2009006410 A MX 2009006410A MX 2009006410 A MX2009006410 A MX 2009006410A MX 2009006410 A MX2009006410 A MX 2009006410A
- Authority
- MX
- Mexico
- Prior art keywords
- oligonucleotide
- peptide
- protein
- polymer conjugates
- polyethyleneglycol
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Abstract
Se describe un conjugado o compuesto que comprende polietilenglicol y un oligonucleátido, en donde al menos un polietilenglicol se liga al extremo 5´ del oligonucleátido y al menos un polietilenglicol se liga al extremo 3´ del oligonucleátido, en donde el peso molecular del polietilenglico ligado al extremo 5´ y 3´ del oligonucleátido es idéntico y es <5000 Da, o en donde el peso molecular del polietilenglicol ligado al extremo 5´ y 3´ del oligonucleátio es diferente.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06127100A EP1935428A1 (en) | 2006-12-22 | 2006-12-22 | Oligonucleotide-polymer conjugates |
PCT/EP2007/064494 WO2008077956A2 (en) | 2006-12-22 | 2007-12-21 | Oligonucleotide-, protein and/or peptide-polymer conjugates |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2009006410A true MX2009006410A (es) | 2009-06-23 |
Family
ID=37969567
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2009006410A MX2009006410A (es) | 2006-12-22 | 2007-12-21 | Conjugados de polimero-oligonucleotido, proteina y/o peptido. |
Country Status (7)
Country | Link |
---|---|
US (1) | US20110136893A1 (es) |
EP (2) | EP1935428A1 (es) |
JP (1) | JP5401323B2 (es) |
AU (1) | AU2007337994B2 (es) |
CA (1) | CA2684165C (es) |
MX (1) | MX2009006410A (es) |
WO (1) | WO2008077956A2 (es) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2550360B1 (en) | 2010-03-24 | 2017-08-30 | Mirrx Therapeutics A/s | Bivalent antisense oligonucleotides |
CA2802089A1 (en) * | 2010-06-11 | 2011-12-15 | Antisense Pharma Gmbh | Method for selective oligonucleotide modification |
EP2453017A1 (en) | 2010-11-12 | 2012-05-16 | Antisense Pharma GmbH | Oligonucleotides for use in prophylaxis and/or treatment of TGF-beta1 and TGF-beta2, TGF-beta2 and TGF-beta3, TGF-beta1 and TGF-beta3, or TGF-beta1, TGF-beta2, and TGF-beta3 mRNA overexpressing diseases |
CN103608042A (zh) * | 2011-04-26 | 2014-02-26 | 雷加多生物科学公司 | 生产peg化的寡核苷酸的方法 |
JP6475226B2 (ja) | 2013-03-27 | 2019-02-27 | イサルナ セラピューティクス ゲゼルシャフト ミット ベシュレンクテル ハフツング | 眼の疾患を防ぐおよび/または治療する方法における使用ための修飾tgf−ベータオリゴヌクレオチド |
PL2978844T3 (pl) * | 2013-03-27 | 2021-01-25 | Isarna Therapeutics Gmbh | Modyfikowane oligonukleotydy tgf-beta2 |
BR112015024764B1 (pt) | 2013-03-27 | 2022-06-28 | Isarna Therapeutics Gmbh | Oligonucleotídeos de tgf-beta modificados, seu uso e composições farmacêuticas que os compreendem |
JP6584868B2 (ja) * | 2015-02-25 | 2019-10-02 | 学校法人 関西大学 | ゲル素材及びその製造方法 |
KR20180103816A (ko) | 2016-02-09 | 2018-09-19 | 오토텔릭 엘엘씨 | 췌장암을 치료하기 위한 조성물과 방법 |
US9758786B2 (en) | 2016-02-09 | 2017-09-12 | Autotelic, Llc | Compositions and methods for treating pancreatic cancer |
KR20220039639A (ko) * | 2020-09-21 | 2022-03-29 | 오토텔릭바이오 주식회사 | 안티센스 올리고뉴클레오타이드 |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3687808A (en) * | 1969-08-14 | 1972-08-29 | Univ Leland Stanford Junior | Synthetic polynucleotides |
DE3788914T2 (de) * | 1986-09-08 | 1994-08-25 | Ajinomoto Kk | Verbindungen zur Spaltung von RNS an eine spezifische Position, Oligomere, verwendet bei der Herstellung dieser Verbindungen und Ausgangsprodukte für die Synthese dieser Oligomere. |
EP0348458B1 (en) * | 1987-11-30 | 1997-04-09 | University Of Iowa Research Foundation | Dna molecules stabilized by modifications of the 3'-terminal phosphodiester linkage and their use as nucleic acid probes and as therapeutic agents to block the expression of specifically targeted genes |
US5403711A (en) * | 1987-11-30 | 1995-04-04 | University Of Iowa Research Foundation | Nucleic acid hybridization and amplification method for detection of specific sequences in which a complementary labeled nucleic acid probe is cleaved |
US5256775A (en) * | 1989-06-05 | 1993-10-26 | Gilead Sciences, Inc. | Exonuclease-resistant oligonucleotides |
US5623065A (en) * | 1990-08-13 | 1997-04-22 | Isis Pharmaceuticals, Inc. | Gapped 2' modified oligonucleotides |
US5149797A (en) * | 1990-02-15 | 1992-09-22 | The Worcester Foundation For Experimental Biology | Method of site-specific alteration of rna and production of encoded polypeptides |
US5220007A (en) * | 1990-02-15 | 1993-06-15 | The Worcester Foundation For Experimental Biology | Method of site-specific alteration of RNA and production of encoded polypeptides |
US5714331A (en) * | 1991-05-24 | 1998-02-03 | Buchardt, Deceased; Ole | Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility |
US5719262A (en) * | 1993-11-22 | 1998-02-17 | Buchardt, Deceased; Ole | Peptide nucleic acids having amino acid side chains |
US5539082A (en) * | 1993-04-26 | 1996-07-23 | Nielsen; Peter E. | Peptide nucleic acids |
US5700922A (en) * | 1991-12-24 | 1997-12-23 | Isis Pharmaceuticals, Inc. | PNA-DNA-PNA chimeric macromolecules |
US5652355A (en) * | 1992-07-23 | 1997-07-29 | Worcester Foundation For Experimental Biology | Hybrid oligonucleotide phosphorothioates |
EP0733059B1 (en) * | 1993-12-09 | 2000-09-13 | Thomas Jefferson University | Compounds and methods for site-directed mutations in eukaryotic cells |
US5652356A (en) * | 1995-08-17 | 1997-07-29 | Hybridon, Inc. | Inverted chimeric and hybrid oligonucleotides |
US20030175238A1 (en) * | 2000-06-30 | 2003-09-18 | Narendra Bam | Chemokine conjugates |
CA2504633A1 (en) * | 2002-11-21 | 2004-06-10 | Archemix Corporation | Multivalent aptamer therapeutics with improved pharmacodynamic properties and methods of making and using the same |
AU2003303636B2 (en) * | 2002-12-26 | 2010-08-05 | Mountain View Pharmaceuticals, Inc. | Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity |
AU2006243218B2 (en) * | 2005-05-05 | 2009-09-17 | Antisense Pharma Gmbh | Use of low doses of oligonucleotides antisense to TGF-beta, VEGF, interleukin-10, c-jun, c-fos or prostaglandin E2 genes in the treatment of tumors |
-
2006
- 2006-12-22 EP EP06127100A patent/EP1935428A1/en not_active Withdrawn
-
2007
- 2007-12-21 AU AU2007337994A patent/AU2007337994B2/en not_active Ceased
- 2007-12-21 US US12/516,439 patent/US20110136893A1/en not_active Abandoned
- 2007-12-21 MX MX2009006410A patent/MX2009006410A/es active IP Right Grant
- 2007-12-21 JP JP2009542105A patent/JP5401323B2/ja not_active Expired - Fee Related
- 2007-12-21 CA CA2684165A patent/CA2684165C/en not_active Expired - Fee Related
- 2007-12-21 WO PCT/EP2007/064494 patent/WO2008077956A2/en active Application Filing
- 2007-12-21 EP EP07858105A patent/EP2121028A2/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
AU2007337994B2 (en) | 2011-08-25 |
WO2008077956A3 (en) | 2008-11-20 |
JP5401323B2 (ja) | 2014-01-29 |
EP2121028A2 (en) | 2009-11-25 |
CA2684165A1 (en) | 2008-07-03 |
AU2007337994A1 (en) | 2008-07-03 |
US20110136893A1 (en) | 2011-06-09 |
CA2684165C (en) | 2013-12-03 |
JP2010512773A (ja) | 2010-04-30 |
WO2008077956A2 (en) | 2008-07-03 |
EP1935428A1 (en) | 2008-06-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2009006410A (es) | Conjugados de polimero-oligonucleotido, proteina y/o peptido. | |
WO2006124737A3 (en) | Molecular constructs suitable for targeted conjugates | |
MY154909A (en) | Novel thiophene derivatives | |
UA95959C2 (en) | Leptomycin derivatives | |
IL179633A0 (en) | Drug compositions, fusions and conjugates | |
NZ588884A (en) | Cross-linkers and their uses | |
IL229304A (en) | Compounds 1 ', 3' - Imaging Converts - 4 - Phenyl - 3, 4, 5, 6 - Tetrahydro - 2h, 1'h, [1, 4 '] Bipyridinyl - 2' - lozenges, pharmaceutical preparations containing them and their use | |
TW200700406A (en) | Novel thiophene derivatives | |
TW200716591A (en) | Novel thiophene derivatives | |
EA200800657A1 (ru) | Способ приготовления очищенных конъюгатов лекарственных средств | |
TW200738670A (en) | Novel thiophene derivatives | |
ZA200807274B (en) | Novel pyridine derivatives | |
TW200635576A (en) | Releasable polymeric conjugates based on aliphatic biodegradable linkers | |
WO2009099670A3 (en) | Oligomer-cannabinoid conjugates | |
EP2065057A3 (en) | Chelating conjugates having a substituted aromatic moiety and derivatives thereof | |
FR2891314B1 (fr) | Bras d'injecteur anti-cokefaction. | |
DE602005026182D1 (de) | Herstellung von insulinkonjugaten | |
MX2010004899A (es) | Conjugados de neurturina novedosos para uso farmaceutico. | |
DK1327146T3 (da) | Forbindelse med et forgrenet linkermolekyle | |
GB2453402A (en) | Bis-pyyrolo[2.1.-c] benzodiazepine-anthraquinone conjugates as antitumour agents and a process for the preparation thereof | |
WO2006065867A3 (en) | Polymer-linked pseudomonas exotoxin immunotoxin | |
ATE506571T1 (de) | Hydrolyseresistente polyamidzusammensetzungen und daraus geformte artikel | |
BRPI0313645A2 (pt) | composições de inalação com relações de droga elevadas. | |
WO2005002516A3 (en) | Leukocyte internalized peptide-drug conjugates | |
WO2008067495A3 (en) | Chemotherapeutic conjugates and methods of use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |